title: Treating BCG-induced disease in children.
abstract: BACKGROUND
  Bacillus Calmette-Guerín (BCG) is a live attenuated vaccine to prevent tuberculosis, routinely administered at birth as part of the World Health Organization global expanded immunisation programme. Given intradermally, it can cause adverse reactions, including local, regional, distant and disseminated manifestations that may cause parental distress. Rarely, it can cause serious illness and even death. Among those patients with immunocompromised conditions, such as the human immunodeficiency virus (HIV) infection, the complication rate is even higher.
  
  
  OBJECTIVE
  To assess the effects of different interventions for treating BCG-induced disease in children.
  
  
  METHODS
  The following databases were searched: the Cochrane Infectious Diseases Group Specialized Register and Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library (The Cochrane Library 2012, Issue 4); MEDLINE (1966 to November 2012); EMBASE (1947 to November 2012); and LILACS (1980 to November 2012). The metaRegister of Controlled Trials (mRCT) and the WHO trials search portal. Conference proceedings for relevant abstracts and experts were also contacted to identify studies. No language restrictions were applied.
  
  
  METHODS
  Randomized controlled trials (RCTs) comparing any medical or surgical treatment modality for BCG-induced disease in children.
  
  
  METHODS
  Two authors independently evaluated titles, applied inclusion criteria, and assessed the risk of bias of studies. The primary outcomes were the failure rate of therapies for all types of BCG vaccine-induced complications and the time to resolution of illness measured in months. The secondary outcomes were death from BCG vaccine-induced disease and the all-cause mortality. Risk ratios (RRs) were used as measure of effect for dichotomous outcomes and mean differences for continuous outcomes.
  
  
  RESULTS
  Five RCTs analysing 341 children addressed the primary outcomes and were included. Four arms compared oral antibiotics to no intervention or placebo, one arm evaluated needle aspiration compared to no intervention, and another evaluated the use of locally instilled isoniazid versus oral erythromycin.Two small studies evaluated oral isoniazid; we are uncertain of whether this intervention has an effect on clinical failure (RR 1.48; 95% Confidence Interval (CI) 0.79 to 2.78; 54 participants, two studies, very low quality evidence). Similarly, for oral erythromycin, we are uncertain if there is an effect (clinical failure RR 1.03; 95% CI 0.70 to 1.53; 148 participants, three studies, very low quality evidence), and for oral isoniazid plus rifampicin (clinical failure, RR 1.20; 95% CI 0.51 to 2.83; 35 participants, one study, very low quality evidence).In patients with lymphadenitis abscess, needle aspiration may reduce clinically persistent BCG-induced disease at 6 to 9 months of follow-up (RR 0.13; 95% CI 0.03 to 0.55; 77 participants, one study, low quality evidence). In another study of patients with the same condition, aspiration plus local instillation of isoniazid reduces time to clinical cure compared to aspiration plus oral erythromycin (mean difference 1.49 months less; 95% CI 0.82 to 2.15 less; 27 participants, one study).No RCTs of HIV-infected infants with a BCG-induced disease evaluated the use of antibiotics or other therapies for reducing the rate of clinical failure or the time to clinical resolution. No data on mortality secondary to the interventions for treating BCG-induced disease were reported.
  
  
  CONCLUSIONS
  It is unclear if oral antibiotics (isoniazid, erythromycin, or a combination of isoniazid plus rifampicin) are effective for the resolution of BCG-induced disease. Most non-suppurated lymphadenitis will resolve without treatment in 4 to 6 months. Patients with lymphadenitis abscess might benefit from needle aspiration and possibly local instillation of isoniazid could shorten recovery time. Included studies were generally small and could be better conducted. Further research should evaluate the use of needle aspiration and local instillation of isoniazid in fluctuant nodes. Therapeutic and preventive measures in HIV-infected infants could be important given the higher risk of negative outcomes in this group.
authors: Centre for Evidence Based Practice Tecnológico de Monterrey, Escuela de Medicina-ITESM, Monterrey NL, Mexico.carlos.cuello@itesm.mx.
authors: Carlos A
authors: CA
authors: Cuello-García
authors: Giordano
authors: G
authors: Pérez-Gaxiola
authors: Carlos
authors: C
authors: Jiménez Gutiérrez
mesh_terms: D000038:Abscess / Q000382:microbiology / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D004917:Erythromycin / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007538:Isoniazid / Q000627:therapeutic use; D008199:Lymphadenitis / Q000382:microbiology / Q000628:therapy*; D009163:Mycobacterium bovis; D016032:Randomized Controlled Trials as Topic; D012293:Rifampin / Q000627:therapeutic use; D013396:Suction / Q000379:methods
chemical_list: D000276:Adjuvants, Immunologic; D000904:Antibiotics, Antitubercular; D001500:BCG Vaccine; D004917:Erythromycin; D007538:Isoniazid; D012293:Rifampin